Several clinical studies focused on investigating the effects of activators of the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) on progression of mainly diabetes-induced CKD [3,4]. This evidence concerns the gene NFE2L2 and diabetes mellitus.